Literature DB >> 7384438

Percutaneous transluminal angioplasty and case selection.

A Motarjeme, J W Keifer, A J Zuska.   

Abstract

The application of percutaneous transluminal angioplasty (PTA) in the treatment of arteriosclerotic occlusive disease is relatively new in the United States. To ascertain more data on case selection, procedure, and success rate, the authors evaluated 100 consecutive patients as possible candidates for treatment with PTA. Patients were divided into five groups on the basis of procedural acceptability. PTA was indicated for 71% of the patients. One hundred seventeen arteries were treated in 56 patients, with a primary success rate of 91.5% of the arteries (82% of the patients). This success rate indicates that PTA is a potentially effective treatment for patients with arteriosclerotic occlusive disease.

Entities:  

Mesh:

Year:  1980        PMID: 7384438     DOI: 10.1148/radiology.135.3.7384438

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  5 in total

1.  Percutaneous transluminal angioplasty of peripheral vascular disease: a two-year experience.

Authors:  R F Colapinto; E P Harries-Jones; K W Johnston
Journal:  Cardiovasc Intervent Radiol       Date:  1980       Impact factor: 2.740

2.  Non-surgical management of peripheral vascular disease.

Authors: 
Journal:  Br Med J       Date:  1980-11-08

3.  Superficial femoral artery occlusion: observations that influence patient selection criteria for angioplasty.

Authors:  M L Kinnison; S Kadir
Journal:  Cardiovasc Intervent Radiol       Date:  1984       Impact factor: 2.740

4.  The role of percutaneous transluminal angioplasty for atherosclerotic disease of the lower extremities.

Authors:  J G Mosley; S M Gulati; M Raphael; A Marston
Journal:  Ann R Coll Surg Engl       Date:  1985-03       Impact factor: 1.891

5.  Percutaneous transluminal angioplasty.

Authors:  R Curry; L Johnston
Journal:  Ulster Med J       Date:  1982
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.